(19)
(11) EP 2 720 693 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.05.2017 Bulletin 2017/20

(45) Mention of the grant of the patent:
08.03.2017 Bulletin 2017/10

(21) Application number: 12734829.0

(22) Date of filing: 15.06.2012
(51) International Patent Classification (IPC): 
A61K 31/352(2006.01)
A61K 31/36(2006.01)
A61K 31/353(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/EP2012/061524
(87) International publication number:
WO 2012/172090 (20.12.2012 Gazette 2012/51)

(54)

CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS

CHROMAN-ÄHNLICHE CYCLISCHE PRENYLFLAVONOIDE ZUR MEDIZINISCHEN INTERVENTION BEI NEUROLOGISCHEN ERKRANKUNGEN

CHROMANE-SIMILAIRES PRÉNYLFLAVONOÏDES CYCLIQUES POUR L'INTERVENTION MÉDICALE LORS DE TROUBLES NEUROLOGIQUES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 17.06.2011 EP 11170298

(43) Date of publication of application:
23.04.2014 Bulletin 2014/17

(60) Divisional application:
17159592.9

(73) Proprietor: Aigner, Ludwig
83395 Freilassing (DE)

(72) Inventors:
  • PRIGLINGER, Eleni
    4060 Leonding (AT)
  • COUILLARD-DESPRES, Sébastien
    5071 Wals-Siezenheim (AT)
  • RIVERA, Francisco Javier
    5090000 Valdivia (CL)
  • RIEPL, Herbert
    85221 Dachau (DE)
  • URMANN, Corinna
    94469 Deggendorf (DE)
  • BIENDL, Martin
    84094 Elsendorf (DE)
  • AIGNER, Ludwig
    83395 Freilassing (DE)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)


(56) References cited: : 
WO-A1-2008/095189
WO-A2-2010/006184
US-A1- 2004 063 612
WO-A2-2007/016578
IN-A- 921C HE2 010
US-A1- 2008 031 986
   
  • YEON CHOI ET AL: "In vitro BACE-1?Inhibitory Phenolic Components from the Seeds of Psoralea corylifolia", PLANTA MEDICA, vol. 74, no. 11, 1 September 2008 (2008-09-01), pages 1405-1408, XP055038491, ISSN: 0032-0943, DOI: 10.1055/s-2008-1081301
  • DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KIM, YEONG SEOP ET AL: "Oral administration of Psoralea seed extracts for preventing and treating neurodegenerative diseases", XP002683764, retrieved from STN Database accession no. 2008:694540 -& KR 100 833 652 B1 (KOREA RES INST CHEM TECHNOLOGY) 29 May 2008 (2008-05-29)
  • MING HONG LEE ET AL: "Prenylflavones from Psoralea corylifolia Inhibit Nitric Oxide Synthase Expression through the Inhibition of I-[kappa]B-[alpha] Degradation in Activated Microglial Cells", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 28, no. 12, 1 January 2005 (2005-01-01), pages 2253-2257, XP055038450, ISSN: 0918-6158, DOI: 10.1248/bpb.28.2253
  • DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KIM, JEONG AE ET AL: "Xanthohumol derivatives for preventing and treating angiogenesis-caused diseases", XP002683765, retrieved from STN Database accession no. 2010:474586 -& KR 2010 0037963 A (IND ACADEMIC COOP [KR]) 12 April 2010 (2010-04-12)
  • DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; REN, LILI ET AL: "Active compound extracted from Fordia cauliflora for preventing and treating senile dementia, its preparation and application", XP002683766, retrieved from STN Database accession no. 2006:479888
  • JUNG KEUN CHO ET AL: "Inhibition and structural reliability of prenylated flavones from the stem bark ofon -secretase (BACE-1)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 10, 16 March 2011 (2011-03-16), pages 2945-2948, XP028208755, PERGAMON, ELSEVIER SCIENCE, GB ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.03.060 [retrieved on 2011-03-27]
  • HAK JU LEE ET AL: "Protection of prenylated flavonoids from mori cortex radicis (Moraceae) against nitric oxide-induced cell death in neuroblastoma SH-SY5Y cells", ARCHIVES OF PHARMACAL RESEARCH, vol. 35, no. 1, 1 January 2012 (2012-01-01), pages 163-170, XP055038678, ISSN: 0253-6269, DOI: 10.1007/s12272-012-0118-7
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).